MCM2

Across TCGA pan-cancer cohorts, MCM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MCM2 data layer compared with 30 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MCM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

COAD, LSCC, and LUAD are the cancer types where MCM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.884	1.000	.026	36	view →
LSCC	DFS	Median	All	0.823	0.607	.004	19	view →
LUAD	OS	Median	II,III,IV	0.329	0.913	.001	17	view →
HNSC	OS	Tertile	All	0.784	0.922	.011	9	view →
CCRCC	OS	Quartile	All	0.523	1.000	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MCM2–COAD (DFS)

Open the COAD breakdown →